Menopause Perspectives and Treatment of Asian Women

 

 Buy Article Permissions and Reprints

ABSTRACT

This review summarizes the published literature on menopausal symptoms and concerns from the perspective of Asian menopausal women, compares and contrasts common menopausal symptoms between the Asian and the Western postmenopausal populations, and highlights considerations from the perspective of clinical practice. In contrast to menopausal symptomatology described in the Western populations, musculoskeletal symptoms and sleeplessness, rather than vasomotor symptoms, dominate the clinical presentation in menopausal Asian women; decreased sexual function, although an important issue, is not commonly brought up for discussion in the context of bothersome menopausal symptoms by Asian women. The epidemiology of the common disorders of aging, such as osteoporosis, breast cancer, and cardiovascular disease, differs between the Asian and Western populations. Awareness and the use of hormone replacement therapy (HRT) are generally low and noted to vary significantly among populations from different Asian countries. The perspectives, and the spectrum of symptom burden relating to reproductive aging in the Asian menopausal women are unique; an appreciation of these distinctions will allow for better tailoring of management paradigms to accommodate the diversified cultural, customary, and religious backgrounds and the socioeconomic disparities that exist among the various Asian populations.

REFERENCES

• 1 Freeman E W, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review.  Climacteric. 2007;  10(3) 197-214
  CrossrefPubMedGoogle Scholar
• 2 Ho S C, Chan S G, Yip Y B, Cheng A, Yi Q, Chan C. Menopausal symptoms and symptom clustering in Chinese women.  Maturitas. 1999;  33(3) 219-227
  CrossrefPubMedGoogle Scholar
• 3 Pan H-A, Wu M-H, Hsu C C, Yao B L, Huang K E. The perception of menopause among women in Taiwan.  Maturitas. 2002;  41(4) 269-274
  CrossrefPubMedGoogle Scholar
• 4 Chang C, Chang C H. Menopause and hormone using experiences of Chinese women in Taiwan.  Health Care Women Int. 1996;  17(4) 307-318
  CrossrefPubMedGoogle Scholar
• 5 Chim H, Tan B HI, Ang C C, Chew E MD, Chong Y S, Saw S M. The prevalence of menopausal symptoms in a community in Singapore.  Maturitas. 2002;  41(4) 275-282
  CrossrefPubMedGoogle Scholar
• 6 Tan D, Darmasetiawan S, Haines C J Expert Panel on Menopause in Asian Women et al. Guidelines for hormone replacement therapy of Asian women during the menopausal transition and thereafter.  Climacteric. 2006;  9(2) 146-151
  CrossrefPubMedGoogle Scholar
• 7 Asia Pacific Menopause Federation .Asia-Pacific Menopause Federation consensus statement on the management of the menopause; April 2008. http://Available at: www.apmf.net Accessed June 3, 2010
  PubMedGoogle Scholar
• 8 Haines C J, Xing S M, Park K-H, Holinka C F, Ausmanas M K. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study.  Maturitas. 2005;  52(3–4) 264-276
  CrossrefPubMedGoogle Scholar
• 9 Taechakraichana N, Holinka C F, Haines C J, Subramaniam R, Tian X W, Ausmanas M K. Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study.  Climacteric. 2007;  10(3) 225-237
  CrossrefPubMedGoogle Scholar
• 10 Limpaphayom K K, Darmasetiawan M S, Hussain R I, Burriss S W, Holinka C F, Ausmanas M K. Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study.  Climacteric. 2006;  9(3) 204-214
  CrossrefPubMedGoogle Scholar
• 11 Huang K-E, Xu L, I N N, Jaisamrarn U. The Asian Menopause Survey: knowledge, perceptions, hormone treatment and sexual function.  Maturitas. 2010;  65(3) 276-283
  CrossrefPubMedGoogle Scholar
• 12 Genazzani A R, Schneider H P, Panay N, Nijland E A. The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy.  Gynecol Endocrinol. 2006;  22(7) 369-375
  CrossrefPubMedGoogle Scholar
• 13 Huang K-E, Baber R. Updated clinical recommendations for the use of tibolone in Asian women.  Climacteric. 2010;  , May 5 (Epub ahead of print)
  PubMedGoogle Scholar
• 14 Haines C J, Rong L, Chung T KH, Leung D HY. The perception of the menopause and the climacteric among women in Hong Kong and southern China.  Prev Med. 1995;  24(3) 245-248
  CrossrefPubMedGoogle Scholar
• 15 Lock M, Kaufert P, Gilbert P. Cultural construction of the menopausal syndrome: the Japanese case.  Maturitas. 1988;  10(4) 317-332
  CrossrefPubMedGoogle Scholar
• 16 Obermeyer C M. Menopause across cultures: a review of the evidence.  Menopause. 2000;  7(3) 184-192
  CrossrefPubMedGoogle Scholar
• 17 Sukwatana P, Meekhangvan J, Tamrongterakul T, Tanapat Y, Asavarait S, Boonjitrpimon P. Menopausal symptoms among Thai women in Bangkok.  Maturitas. 1991;  13(3) 217-228
  CrossrefPubMedGoogle Scholar
• 18 Chaikittisilpa S, Limpaphayom K, Chompootweep S, Taechakraichana N. Symptoms and problems of menopausal women in Klong Toey slum.  J Med Assoc Thai. 1997;  80(4) 257-261
  PubMedGoogle Scholar
• 19 Zhao G, Wang L, Yan R, Dennerstein L. Menopausal symptoms: experience of Chinese women.  Climacteric. 2000;  3(2) 135-144
  CrossrefPubMedGoogle Scholar
• 20 Punyahotra S, Dennerstein L, Lehert P. Menopausal experiences of Thai women. Part 1: Symptoms and their correlates.  Maturitas. 1997;  26(1) 1-7
  CrossrefPubMedGoogle Scholar
• 21 Wasti S, Robinson S C, Akhtar Y, Khan S, Badaruddin N. Characteristics of menopause in three socioeconomic urban groups in Karachi, Pakistan.  Maturitas. 1993;  16(1) 61-69
  CrossrefPubMedGoogle Scholar
• 22 Rossouw J E, Anderson G L, Prentice R L Writing Group for the Women's Health Initiative Investigators et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;  288(3) 321-333
  CrossrefPubMedGoogle Scholar
• 23 Anderson G L, Limacher M, Assaf A R Women's Health Initiative Steering Committee et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.  JAMA. 2004;  291(14) 1701-1712
  CrossrefPubMedGoogle Scholar
• 24 Naftolin F, Schneider H PG, Sturdee D W Executive Committee of the International Menopause Society et al. Guidelines for hormone treatment of women in the menopausal transition and beyond.  Climacteric. 2004;  7(4) 333-337
  CrossrefPubMedGoogle Scholar
• 25 Skouby S O, Al-Azzawi F, Barlow D European Menopause and Andropause Society et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.  Maturitas. 2005;  51(1) 8-14
  CrossrefPubMedGoogle Scholar
• 26 North American Menopause Society . Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of the North American Menopause Society.  Menopause. 2004;  11(6 Pt 1) 589-600
  CrossrefPubMedGoogle Scholar
• 27 Redactor G. Posición Latinamericana en relación con el estado actual de la terapia hormonal.  Ginecol Obstet Mex. 2005;  73 205-211
  PubMedGoogle Scholar
• 28 Pines A, Sturdee D W, Birkhauser M H, Schneider H PG, Gambacciani M, Panay N. for the Board of the International Menopause Society . IMS updated recommendation on postmenopausal hormone therapy.  Climacteric. 2007;  10 181-194
  CrossrefPubMedGoogle Scholar
• 29 Utian W H, Shoupe D, Bachmann G, Pinkerton J V, Pickar J H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.  Fertil Steril. 2001;  75(6) 1065-1079
  CrossrefPubMedGoogle Scholar
• 30 Nijland E A, Weijmar Schultz W C, Nathorst-Boös J LISA study investigators et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in natural menopausal women: results of a randomized active-controlled trial.  J Sex Med. 2008;  5 646-656
  CrossrefPubMedGoogle Scholar
• 31 Hammar M L, van de Weijer P, Franke H R, Pornel B, von Mauw E M, Nijland E A. Total Study Investigators Group . Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.  Br J Obstet Gynaecol. 2007;  114 1522-1529
  PubMedGoogle Scholar
• 32 Pan H A, Wang S T, Pai M C, Chen C H, Wu M H, Huang K E. Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison.  J Reprod Med. 2003;  48(5) 375-380
  PubMedGoogle Scholar
• 33 Wu M H, Pan H A, Wang S T, Hsu C C, Chang F M, Huang K E. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy.  Climacteric. 2001;  4(4) 314-319
  PubMedGoogle Scholar
• 34 Yang T S, Tsan S H, Chen C R, Chang S P, Yuan C C. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women.  Zhonghua Yi Xue Za Zhi (Taipei). 1999;  62(5) 308-315
  PubMedGoogle Scholar
• 35 Lam P M, Cheung G W, Shek D T, Lee D T, Haines C J, Chung T K. A randomized, placebo-controlled, crossover study of tibolone (Livial) on menopause symptoms, psychological well-being, and dyadic relationship of postmenopausal Chinese women and their spouses.  Menopause. 2004;  11(4) 416-422
  CrossrefPubMedGoogle Scholar
• 36 Koh K K, Ahn J Y, Jin D K et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study.  Arterioscler Thromb Vasc Biol. 2003;  23(10) 1889-1894
  CrossrefPubMedGoogle Scholar
• 37 Lee K B, Lee J M, Yoon J H, Park C Y. The safety of tibolone in epithelial ovarian cancer patients.  Maturitas. 2006;  55(2) 156-161
  CrossrefPubMedGoogle Scholar
• 38 Cummings S R, Ettinger B, Delmas P D LIFT Trial Investigators et al. The effects of tibolone in older postmenopausal women.  N Engl J Med. 2008;  359(7) 697-708
  CrossrefPubMedGoogle Scholar
• 39 White R H, Keenan C R. Effects of race and ethnicity on the incidence of venous thromboembolism.  Thromb Res. 2009;  123(Suppl 4) S11-S17
  CrossrefPubMedGoogle Scholar
• 40 Tan K S, Rashid A, Tan C T. Venous thromboembolism in ischemic stroke in Asia.  Neurology Asia. 2008;  13 95-101
  PubMedGoogle Scholar
• 41 Valdivia I, Campodónico I, Tapia A, Capetillo M, Espinoza A, Lavín P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women.  Fertil Steril. 2004;  81(3) 617-623
  CrossrefPubMedGoogle Scholar
• 42 Bruce D, Robinson J, McWilliams S, Reddy M, Fentiman I, Rymer J. Long-term effects of tibolone on mammographic density.  Fertil Steril. 2004;  82(5) 1343-1347
  CrossrefPubMedGoogle Scholar
• 43 Krebs E E, Ensrud K E, MacDonald R, Wilt T J. Phytoestrogens for treatment of menopausal symptoms: a systematic review.  Obstet Gynecol. 2004;  104(4) 824-836
  CrossrefPubMedGoogle Scholar
• 44 Geller S E, Studee L. Soy and red clover for mid-life and aging.  Climacteric. 2006;  9(4) 245-263
  CrossrefPubMedGoogle Scholar
• 45 Liu H, Yang D N. Clinical observations on treatment of 86 peri-climacteric syndrome cases by point cutgut embedding.  Shanghai J Acupunct Mox. 2007;  26 5-7
  PubMedGoogle Scholar
• 46 Zhou J, Qin Z Y, Li W L et al. Clinical observation on therapeutic effect of electroacupuncture at Sanyinjiao (SP 6) on peri-menopausal syndrome [in Chinese].  Zhongguo Zhen Jiu. 2006;  26(9) 617-620
  PubMedGoogle Scholar
• 47 Cho S-H, Whang W-W. Acupuncture for vasomotor menopausal symptoms: a systematic review.  Menopause. 2009;  16(5) 1065-1073
  CrossrefPubMedGoogle Scholar
• 48 Chow L. Breast cancer incidence rising in Asian women at younger age: Sunitinib shows potential as treatment for metastatic disease.  First Asian Breast Cancer Conference November 22, 2009 New Delhi, India;
  PubMedGoogle Scholar
• 49 Chang K-J, Kuo W-H, Wang M-Y. The epidemiology of breast cancer in Taiwan [in Chinese with English abstract].  J Oncol Soc. 2008;  24 85-93
  PubMedGoogle Scholar
• 50 Ravdin P M, Cronin K A, Howlader N et al. The decrease in breast-cancer incidence in 2003 in the United States.  N Engl J Med. 2007;  356(16) 1670-1674
  CrossrefPubMedGoogle Scholar
• 51 Greendale G A, Reboussin B A, Sie A Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density.  Ann Intern Med. 1999;  130(4 Pt 1) 262-269
  PubMedGoogle Scholar
• 52 Habel L A, Capra A M, Oestreicher N et al. Mammographic density in a multiethnic cohort.  Menopause. 2007;  14(5) 891-899
  CrossrefPubMedGoogle Scholar
• 53 Grodstein F, Manson J E, Stampfer M J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.  J Womens Health (Larchmt). 2006;  15(1) 35-44
  CrossrefPubMedGoogle Scholar

Ko-En HuangM.D. F.A.C.O.G. 

Professor, Department of Obstetrics and Gynecology and Center for Menopause and Reproductive Medicine Research

Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University School of Medicine, 123 Ta-Pei Road, Nioa-Sung Hsiang, Kaohsiung 833, Taiwan

Email: khuang@adm.cgmh.org.tw